NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
China Aoxing Pharmaceutical Company, Inc. »20/01/2010 [Industry news]
China Aoxing Pharmaceutical Corp. Announces Appointment of New Chief Financial Officer

China Aoxing Pharmaceutical Company, Inc., a pharmaceutical company specialising in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it has appointed Dr. Hui Shao as Chief Financial Officer, effective immediately.

 
China Aoxing Pharmaceutical Company, Inc., a pharmaceutical company specialising in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it has appointed Dr. Hui Shao as Chief Financial Officer, effective immediately. \"We are very delighted to welcome Dr. Shao into his new appointment as Chief Financial Officer of the Company,\" said Zhenjiang Yue, Chairman and CEO of China Aoxing. \"We believe Dr. Shao\'s global vision and expertise in the healthcare industry will enhance our operations and financial capabilities immediately as our company embarks on a new era of growth and international endeavors. He will certainly strengthen our profile as a publicly listed company.\" Dr. Shao brings a broad business and financial acumen with over 14 years of extensive financial, accounting, private investment and strategic business development experience across various aspects of the global healthcare industry. Since 2007, Dr. Shao has served as the Company\'s Vice President of Finance. Prior to joining the Company, Dr. Shao was a Senior Analyst at Mehta Partners and Kamunting Street Capital Management in New York, where he was responsible for a healthcare investment portfolio of over $100 million across North American and European companies. Dr. Shao was a Principal Scientist, leading metabolic disease and oncology projects at Roche Pharmaceuticals, before he started his career on Wall Street. Dr. Shao earned his MBA in Finance and Accounting from the Stern School of Business, New York University. He earned his Ph.D. in Bioorganic Chemistry from the University of California, San Diego. He is a Chartered Financial Analyst (CFA) and a member of the New York Society of Security Analysts (NYSSA). Dr. Shao commented, \"I am excited to have the opportunity to expand my role at the Company. Our business is making significant progress on every front. I look forward to seeing these endeavors to fruition and believe that China Aoxing will be in an excellent position to benefit from the rapid growth and market dynamics of its pain management therapeutics.\" With Dr. Shao\'s appointment, Ms. Hongyue Hao will step down as the Acting CFO. Ms. Hao will continue to be the Vice General Manager of Financial Operations and Reporting of Hebei Aoxing Pharmaceutical Group Company, Inc., the main operating subsidiary of China Aoxing.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.